Treatment of Covid-19: the Institut Pasteur de Lille has found a patient for its clinical trial

It was an essential starting point. THE’Institut Pasteur de Lille (North) just announced having recruited a patient for his clinical test phase 2/3 aiming to measure the efficiency of its treatment against Covid-19.

Test carried out by 40 doctors

The institute has been working for several months on the effectiveness of clofoctol in the early management of Covid patients and the prevention of hospitalization. The clinical trial, which has received the “National Research Priority” label, is carried out by around 40 general practitioners from Hauts de France.

As a reminder, in the spring of 2020, teams from the Institut Pasteur de Lille identified clofoctol, a molecule that is particularly effective in inhibiting the replication of the virus against SARS-CoV-2 in vitro.

This molecule is the active principle of a drug marketed in Europe in the form of a suppository and which has already had marketing authorization in France for the treatment of nasopharyngitis.

“Bring important elements”

It could therefore be repositioned as a treatment for Covid-19. It is with this in mind that the clinical trial will be carried out on a man /

“We are optimistic that the phase 2/3 trial will provide important elements relating to the usefulness of clofoctol in the treatment of the early stages of Covid-19”, comments Benoît Déprez, project manager and scientific director of the Pastor Institute.

An important hope in the fight against the virus.

Has this article been useful to you? Note that you can follow Lille Actu in the Mon Actu space. In one click, after registration, you will find all the news of your favorite cities and brands.

–